Related Experiment Video
Updated: Jul 17, 2025
08:58
Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis
Published on: January 5, 2017
12.3K
Emerging oral drug options for ulcerative colitis
Silvia Salvatori1,2, Benedetto Neri1,2, Irene Marafini1,2
1Gastroenterology Unit, Policlinico Universitario Tor Vergata, Rome, Italy.
Expert Opinion on Emerging Drugs
|September 5, 2023
Summary
New oral drugs offer hope for ulcerative colitis (UC) patients unresponsive to current treatments. Research is exploring novel small-molecule therapies to improve efficacy and safety in managing moderate-to-severe UC.
Area of Science:
- Gastroenterology and Pharmacology
- Drug Development and Clinical Trials
Background:
- Existing ulcerative colitis (UC) treatments are ineffective for one-third of patients with moderate-to-severe disease.
- Many UC patients experience adverse drug reactions, necessitating novel therapeutic approaches.
Purpose of the Study:
- To review emerging oral drugs for ulcerative colitis (UC) currently in clinical trials or nearing clinic entry.
- To provide an overview of the latest advancements in oral pharmacotherapy for UC management.
Main Methods:
- A systematic literature search was conducted on PubMed.
- Keywords included 'oral drugs ulcerative colitis,' 'ulcerative colitis clinical trials,' and 'UC phase 2 and 3 trials.'
- Exclusions comprised case reports, case series, phase 1 and 4 studies, and studies on already approved therapies.
Main Results:
- The future of UC treatment is likely to involve a diverse range of small-molecule oral drugs.
- These novel compounds exhibit varied efficacy and safety profiles, even within the same drug class.
Conclusions:
- Predicting patient response to new oral UC therapies is crucial for optimizing treatment outcomes.
- Personalized medicine approaches, including pretreatment patient stratification, can enhance efficacy, safety, and resource allocation.
More Related Videos
Related Concept Videos
01:29Drugs for Treatment of Ulcerative Colitis in IBD
173
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
173
01:24Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents
551
In the intricate landscape of the gastric lumen, excessive acid secretion disrupts the natural defense mechanisms, weakening the mucus-bicarbonate barrier. This vulnerability allows pepsin to infiltrate epithelial cells, digesting mucosal proteins and triggering erosion, leading to ulcer formation.
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
551
01:20Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
493
The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
493
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
149
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
149
01:29Inflammatory Bowel Disease IV: Pharmacological Management
152
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
152
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
195
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
195